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licenses/by-nc-nd/4.0/).Rationale & Objective: Epoetin alfa-epbx is a
biosimilar to the reference product, epoetin alfa.
We compare the safety of epoetin alfa-epbx
versus epoetin alfa based on a pooled analysis of
findings from 2 randomized, double-blind,
comparative clinical studies, and report new data
for the long-term safety of epoetin alfa-epbx.
Study Design: Pooled analyses of previously
conducted studies.
Setting & Participants: Hemodialysis patients with
anemia.
Interventions: Data from patients who received 1
or more subcutaneous or intravenous doses of
study drug were integrated across route of
administration in combined randomized groups
(epoetin alfa-epbx, n = 423; epoetin alfa, n = 426).
Data from patients who received 1 or more doses
of epoetin alfa-epbx in either open-label extension
trial were integrated across route of
administration in a combined long-term safety
studies group (n = 576).
Outcomes: Adverse events (AEs), immunogenicity,
and other outcomes were assessed.
Results: Incidences of treatment-emergent AEs,
serious AEs, and discontinuation of study drug
treatment because of treatment-emergent AEs
were similar between combined randomized
epoetin alfa-epbx and epoetin alfa, which had
mean treatment durations of 18.1 and 17.7
weeks, respectively. Incidences of treatment-
emergent AEs, serious AEs, and discontinuationKidney Med Vol 1 | Iss 5 | September/October 2019of study drug treatment because of treatment-
emergent AEs were 86.5%, 39.4%, and 6.6%,
respectively, for the combined long-term safety
studies group, which had a mean treatment
duration of 40.0 weeks. In total, 12 patients
across the combined randomized groups (epoetin
alfa-epbx, n = 5; epoetin alfa, n = 7) and 9
patients in the combined long-term safety studies
group tested anti-recombinant human
erythropoietin antibody positive in 1 or more visits
during study conduct. No patient in any group
developed neutralizing antibodies or pure red
blood cell aplasia.
Limitations: Epoetin alfa comparator not included
in the long-term safety studies, greater cumulative
exposure to study drug for epoetin alfa-epbx,
shorter follow-up in the randomized studies, and
potential for selection bias among patients in the
open-label long-term safety studies.
Conclusions: This analysis reinforces previous
conclusions of similar safety profiles between
epoetin alfa-epbx and epoetin alfa. Furthermore,
epoetin alfa-epbx had no unexpected safety
signals during long-term treatment.
Funding: This study was funded by Hospira Inc,
which was acquired by Pfizer Inc in
September 2015.
Trial Registration: ClinicalTrials.gov EPOE-10-13
(NCT01473420); EPOE-10-01 (NCT01473407);
EPOE-11-04 (NCT01628120); EPOE-11-03
(NCT01628107).Anemia is a serious and common complication thatoften develops during chronic kidney disease (CKD)
and worsens with disease progression.1 Anemia in patients
with end-stage kidney disease (ESKD) is frequently severe
and may be associated with higher mortality risk.1-3 The
primary cause of anemia in CKD is insufficient production
of renal erythropoietin, and therefore reduced erythro-
poiesis.4 Epoetin alfa was the first recombinant human
erythropoietin (epoetin) to be approved by the US Food
and Drug Administration (FDA) for treatment of anemia in
patients with CKD.5 In patients with CKD and anemia,
subcutaneous (SC) or intravenous (IV) administration of
epoetin results in clinically significant increases in hemo-
globin (Hb) levels and reduces the need for transfusion.6-8
Biosimilars are biologic drugs that are highly similar to a
licensed (ie, originator or reference) biologic product,“notwithstanding minor differences in clinically inactive
components,” and for which there are no clinically mean-
ingful differences in safety, purity, and potency from the
reference product.9 Biosimilarity is established following a
stepwise approach to comparative assessments of the pro-
posed biosimilar and reference biologic, beginning with
extensive physicochemical and functional characterization
of both products, followed by nonclinical testing and,
finally, clinical studies (ie, clinical pharmacology and
immunogenicity and clinical safety and efficacy).9,10 Thus,
biosimilarity between a proposed biosimilar and reference
biologic is established based on the totality of the evidence
obtained at each stage of development.9
Availability of epoetin biosimilars could potentially
lower the costs of epoetin treatment and provide additional
epoetin treatment options.11 Epoetin alfa-epbx (Retacrit;271
Original ResearchHospira Inc, a Pfizer company) was approved by the FDA
in May 2018 as a biosimilar of epoetin alfa (Epogen/
Procrit; Amgen Inc/Janssen Products LP).12 Epoetin alfa-
epbx has an identical amino acid sequence and similar
carbohydrate composition to epoetin alfa.13,14 Pharmaco-
kinetic and pharmacodynamic equivalence of single and
multiple SC doses of epoetin alfa-epbx to epoetin alfa
was established in 2 pharmacokinetic/pharmacodynamic
studies conducted in healthy males.15,16
Two comparative, randomized, double-blind, clinical
studies, EPOE-10-1317 and EPOE-10-01,18,19 were con-
ducted in hemodialysis (HD) patients with ESKD and
anemia to compare the efficacy of epoetin alfa-epbx with
epoetin alfa, based on maintenance of Hb levels and study
drug dose requirements, and to evaluate safety. Results
from these studies demonstrated equivalence in efficacy
and similar safety of SC-administered (EPOE-10-13)17 and
IV-administered (EPOE-10-01)18,19 epoetin alfa-epbx to
epoetin alfa, supporting the demonstration of bio-
similarity.13,14 Two supportive open-label extension trials
for EPOE-10-13 and EPOE-10-01—studies EPOE-11-0420
and EPOE-11-03,21 respectively—were conducted to
determine the long-term safety in treatment-emergent
adverse events (AEs) of epoetin alfa-epbx.
This analysis compares the safety of epoetin alfa-epbx
versus epoetin alfa based on a pooled analysis of findings
from EPOE-10-13 and EPOE-10-01, with data integrated
across the 2 studies and route of administration, and with
mean exposure to study drug of approximately 18 weeks.
This analysis also provides new data for the long-term
safety of epoetin alfa-epbx based on a pooled analysis of
findings from the open-label extension trials, with data
integrated across the 2 studies and route of administration
and with mean exposure to epoetin alfa-epbx of
40.0 weeks.METHODS
Overview of Studies
An overview of epoetin alfa-epbx clinical development
studies is provided in Table 1.13,14,17-21 EPOE-10-13
(ClinicalTrials.gov identifier NCT01473420) was a
comparative, randomized, double-blind efficacy and
safety study of SC-administered epoetin alfa-epbx versus
epoetin alfa conducted in HD patients with ESKD and
anemia.13,14,17 The study consisted of a screening period,
12- to 18-week titration period, 16-week double-blind
maintenance period, and follow-up visit.13,14,17 Patients
who were receiving stable doses of IV or SC epoetin alfa
during screening and who met all other eligibility criteria
were randomized (1:1) to epoetin alfa-epbx or epoetin
alfa in the titration period.13,14,17 Patients who were
receiving IV epoetin alfa before study initiation were
treated with SC study drug through the titration period,
and those who demonstrated stable SC dosing were re-
randomized (1:1 to SC epoetin alfa-epbx or epoetin alfa)
into the maintenance period.13,14,17 Stable dosing was272defined as meeting all of the following requirements
before entering the maintenance period: change in epoetin
dosing of ≤10% from the mean, mean Hb level of 9.0 to
11.0 g/dL, no more than 1 Hb level result outside of
range from 9.0 to 11.0 g/dL, and no Hb result more
than ± 1 g/dL from the mean Hb level. Patients who were
already receiving SC epoetin alfa before study initiation
were randomized into but not treated in the titration
period; they were directly re-randomized (1:1 to SC
epoetin alfa-epbx or epoetin alfa) into the maintenance
period.13,14,17
EPOE-10-01 (ClinicalTrials.gov identifier NCT01473407)
was a comparative, randomized, multicenter, double-blind
efficacy and safety study of IV-administered epoetin
alfa-epbx versus epoetin alfa conducted in HD patients
with ESKD and anemia.18,19 The study consisted of a
screening period, 24-week treatment period, and follow-
up visit.19 Patients who were receiving stable doses of
IV epoetin alfa during screening and who met all
other eligibility criteria were randomized (1:1) to receive
IV epoetin alfa-epbx or epoetin alfa in the treatment
period.19 EPOE-11-04 and EPOE-11-03 (ClinicalTrials.gov
identifiers NCT01628120 and NCT01628107,
respectively) were supportive open-label extension trials
for EPOE-10-13 and EPOE-10-01, respectively.20,21 In
both studies, epoetin alfa-epbx was administered to all
patients for up to an additional 48 weeks through the
same route of administration as in the initial double-blind
trial.13,14,20,21
All study protocols and amendments were approved by
an independent review board (Quorum Review Institu-
tional Review Board [IRB], Seattle, WA) or local inde-
pendent ethics committee/IRBs (Table S1). All studies
were conducted in compliance with IRB regulations, the
Declaration of Helsinki, the International Conference on
Harmonization guidelines, Good Clinical Practice guide-
lines, and all applicable regulatory requirements. Patients
provided written informed consent before the perfor-
mance of any study-specific procedures.
Patients and Treatments
Inclusion and exclusion criteria have been reported pre-
viously.13,14,17-21 Briefly, EPOE-10-13 and EPOE-10-01
included men and nonpregnant women receiving HD
aged 18 to 80 years with ESKD and anemia who,
before randomization, had stable Hb levels (mean, 9.0-
11.0 g/dL) for 4 or more weeks, were receiving stable
adequate HD for 12 or more weeks, had adequate iron
stores (plasma ferritin > 100 μg/L and transferrin satura-
tion > 20%), and were receiving stable SC (EPOE-10-13
only) or IV epoetin alfa 1 to 3 times per week and did not
require maintenance doses > 600 U/kg/wk of epoetin
alfa.13,14,17-19 EPOE-11-04 and EPOE-11-03 included pa-
tients who previously completed the maintenance period
of study EPOE-10-13 and the treatment period of EPOE-
10-01, respectively.13,14,19-21 In all 4 studies, study drug
dosing was individually titrated to maintain Hb levelsKidney Med Vol 1 | Iss 5 | September/October 2019
Table 1. Overview of Epoetin alfa-epbx Clinical Development Studies
Study (ClinicalTrials.Gov















population (N = 320);
maintenance period:
randomized population,
epoetin alfa-epbx (n = 124);
epoetin alfa (n = 122); safety
population, epoetin alfa-
epbx (n = 122); epoetin alfa
(n = 122)
Titration period: 1-3×/wk
(starting dose 20%-30% lower
than IV epoetin alfa dose
received in last wk of screening)
for 12-18 wk; maintenance
period: 1-3×/wk, at same
weekly dose received in last wk
of titration or screening period,
for 16 wk; 30-d follow-up if not
entering long-term safety study
Mean weekly Hb and mean
weekly dose/kg body weight
















alfa-epbx (N = 173); safety
population: epoetin alfa-
epbx (N = 170)
1-3×/wk, at last dose level
administered in study EPOE-
10-13, for up to 48 wk
Treatment-emergent
adverse events during the
treatment period (primary);
mean Hb and mean weekly















epoetin alfa-epbx (n = 306);
epoetin alfa (n = 306);
safety population: epoetin
alfa-epbx (n = 301); epoetin
alfa (n = 304)
1-3×/wk, at same weekly dose
administered during last wk of
screening, for 24 wk; 30-d
follow-up if not entering long-
term safety study
Mean weekly Hb and mean
weekly dose/kg body weight














alfa-epbx (N = 414); safety
population: epoetin alfa-
epbx (N = 406)
1-3×/wk, at last dose level
administered in study EPOE-
10-01, for up to 48 wk
Treatment-emergent
adverse events during the
treatment period (primary);
mean Hb and mean weekly
dose/kg body weight during
the treatment period
(secondary)
Abbreviations: ESKD, end-stage kidney disease; Hb, hemoglobin; HD, hemodialysis; IV, intravenous.



















Original Researchbetween 9.0 and 11.0 g/dL,13,19 consistent with recom-
mendations in the epoetin alfa US package insert.22,23
Analysis Populations and Assessments
The safety population for the combined randomized
treatment groups comprised patients who received 1 or
more doses of study drug during the maintenance period
in EPOE-10-13 or the treatment period in EPOE-10-01.
Data from patients in these core studies were integrated
across administration route to create combined random-
ized epoetin alfa-epbx and epoetin alfa treatment groups.
This provided a primary safety overview, allowing for a
comparison of safety between study drugs based on the
pooled experience in 2 comparative randomized safety and
efficacy studies. The safety population for the combined
open-label extension trials included all patients who
received 1 or more doses of epoetin alfa-epbx in either
EPOE-11-04 or EPOE-11-03. Data from patients in these
supportive extension trials were integrated across admin-
istration route to create a combined open-label long-term
safety study group. This provided additional safety data,
allowing for evaluation of long-term safety in treatment-
emergent AEs with exposure to epoetin alfa-epbx for up
to an additional 48 weeks following treatment in the core
studies.
Primary safety analyses were conducted on the safety
population for the combined randomized treatment
groups, and supportive safety analyses were performed on
the safety population for the combined open-label long-
term safety study group. Safety assessments included AEs,
serious AEs (SAEs), clinical laboratory analytes, incidences
of out-of-range clinical laboratory analytes, and clinical
laboratory screens (ie, Hb < 8.0 or >12.0 g/dL,
with ± 2.0-g/dL change from baseline in Hb level; red
blood cell count < 1.5 ×106/μL and reticulocyte percent-
age of total erythrocytes <0.5%; alanine or aspartate
transaminase level > 3 times the upper limit of normal
and total bilirubin > 1.5 times the upper limit of normal;
absolute neutrophil count < 1,000/μL; and platelet
count < 100,000/μL and international normalized
ratio > 3.5), electrocardiogram findings, and physical
examination findings (reported descriptively). Vital signs
were collected in the comparative studies. AEs of special
interest were myocardial infarction, cerebrovascular
events, thromboembolic events, hypertension, seizures,
pure red blood cell aplasia (PRCA), and potential allergic
reactions.
Given the onset of treatment-emergent AEs during the
transition of patients from the core study to the long-term
safety study, assignment of individual treatment-emergent
AEs to the core study or the long-term safety study was
made differently in certain instances at the individual study
level and for the integrated AE analysis. If the onset of an
AE was in the interim period between the core study and
the long-term safety study but the AE occurred after the
patient received study drug in the core study, the AE was
assigned to the core study in the integrated analysis.274Similar assignments were performed in EPOE-10-13 for
patients transitioning from the titration period to the
maintenance period. This ensured that all treatment-
emergent AEs would be assigned most conservatively for
the integrated AE analyses.
Immunogenicity was also evaluated throughout the
studies.13,14,17-21 The presence of anti-recombinant human
erythropoietin (anti-rhEPO) antibodies and the potential
neutralizing capacity of such antibodies were assessed.RESULTS
Patients
A total of 430 and 428 patients were randomized to epoetin
alfa-epbx and epoetin alfa, respectively, across the 2
comparative safety and efficacy studies (Fig 1). Of these,
423 and 426 patients received epoetin alfa-epbx and epoetin
alfa, respectively, and comprised the safety populations for
the combined randomized treatment groups. Patient de-
mographics and baseline characteristics were generally well
matched between the 2 combined randomized groups
(Table 2). Mean duration of treatment was 18.1 (standard
deviation [SD], 6.4) and 17.7 (SD, 6.8) weeks for the
combined randomized epoetin alfa-epbx and epoetin alfa
groups, respectively; median duration of treatment was
22.7 (range, 0.0-24.7) and 21.7 (range, 0.0-25.3) weeks,
respectively. Study completion rates were similar between
combined randomized epoetin alfa-epbx (83.9%) and
epoetin alfa (85.7%; Fig 1). Corresponding rates of study
discontinuation due to AEs were 2.4% and 2.3%, respec-
tively. Study drug treatment completion and discontinua-
tion rates were also similar between the combined
randomized groups (Table S2).
A total of 587 patients were enrolled across the 2
supportive open-label extension trials (Fig 1). Of these,
576 patients received epoetin alfa-epbx and comprised the
safety population for the combined open-label long-term
safety study group. Patient demographics and baseline
characteristics of the open-label long-term safety study
group were generally consistent with the combined ran-
domized groups (Table 2). Diabetes and hypertension
were the primary causes of CKD across all groups. Mean
and median durations of treatment were 40.0 (SD, 14.1)
and 47.0 (range, 0.0-65.3) weeks, respectively, for the
combined open-label long-term safety study group. Study
completion rate in the combined open-label long-term
safety study group was 73.6%, and 7.8% of patients dis-
continued the study because of AEs (Fig 1).
Adverse Events
Combined Randomized Controlled Trials
Approximately 75% of patients in both combined
randomized treatment groups experienced 1 or more
treatment-emergent AEs (Table 3). The most common
(incidence ≥ 5%) treatment-emergent AEs were similar
between treatment groups and the most frequently reported












Treated with epoetin alfa-epbx
(n=576)
Combined open-label epoetin alfa-epbx
Completed study, n (%) 424 (73.6)
Discontinued study, n (%)  152 (26.4)
)8.7(54EA
Did not meet 3 (0.5)
eligibility criteria
Lost to follow-up 5 (0.9)
Non-compliance with 11 (1.9)
study drug
Physician decision 2 (0.3)
Withdrawal by patient 24 (4.2)
Other 62 (10.8)
Figure 1. Patient disposition. Study completion and study discontinuation rates for the combined randomized and combined open-
label long-term safety study (LTSS) groups. aPatients were eligible for the open-label LTSSs, EPOE-11-04 and EPOE-11-03, if they
received treatment and completed the required study assessments during the respective core studies: EPOE-10-13 maintenance
period, up to and including week 16 study assessments; and EPOE-10-01 treatment period, up to and including week 24 study
assessments. Patients who discontinued treatment before week 16 of the maintenance period in EPOE-10-13 and before week
24 of the treatment period in EPOE-10-01 were offered treatment with standard-of-care erythropoiesis-stimulating agents (ESAs)
for the rest of the maintenance and treatment periods and were to complete the required week 16 (EPOE-10-13) or week 24
(EPOE-10-01) study assessments to be eligible for enrollment in the LTSS. Enrollment in the LTSS occurred within 28 days after
completion of the maintenance period week 16 study assessments for the EPOE-10-13 core study and after completion of the treat-
ment period week 24 study assessments for the EPOE-10-01 core study. Abbreviation: AE, adverse event.
Original Research(9.5% vs 7.7% for epoetin alfa), arteriovenous fistula-site
complication (7.6% and 7.0%, respectively), and vomiting
(7.6% and 4.9%, respectively; Table 3).
Similarly, the incidence of SAEs (23.9% vs 27.2%) and
treatment-emergent SAEs resulting in death (n = 9 [2.1%]
in each group) were similar between combined random-
ized epoetin alfa-epbx and epoetin alfa (Table 3).
Incidences of the 8 most common SAEs (congestive heart
failure, noncardiac chest pain, cellulitis, osteomyelitis,
pneumonia, fluid overload, hyperkalemia, and dyspnea)
were similar between the 2 combined randomized groups,
and the 3 most frequently reported SAEs for epoetin alfa-
epbx were pneumonia (1.7% vs 2.3% for epoetin alfa),
congestive heart failure (1.2% in each group), and osteo-
myelitis (1.2% and 0.2%, respectively).
Of the 18 deaths reported for the combined random-
ized groups, 8 (n = 1, epoetin alfa-epbx; n = 7, epoetin
alfa) were the result of cardiovascular disease. The
remaining causes of death for the combined randomized
epoetin alfa-epbx group were azotemia associated with
discontinuation of dialysis treatment (n = 3), sepsis,
gastrointestinal hemorrhage, sudden death (unknown
cause), infectious peritonitis, and metabolic encephalop-
athy (n = 1 each); and for the combined randomized
epoetin alfa group, they were aortic stenosis and meta-
static lung cancer (n = 1 each).Kidney Med Vol 1 | Iss 5 | September/October 2019The incidences of treatment-emergent AEs leading
to discontinuation of study drug treatment were
similar between combined randomized epoetin
alfa-epbx (3.1%) and epoetin alfa (3.5%). The incidences
of AEs of special interest were generally low and
similar between the 2 combined randomized groups.
Furthermore, there were no reported cases of PRCA
(Table 4).
Combined Open-label Long-term Safety Study of
Epoetin Alfa-epbx
In the combined open-label long-term safety study group,
498 (86.5%) patients experienced 1 or more treatment-
emergent AEs. The most common (incidence ≥ 5%)
treatment-emergent AEs were anemia, arteriovenous
fistula-site complication, back pain, cough, diarrhea,
dizziness, dyspnea, headache, hypotension, hyperkalemia,
hypertension, muscle spasms, nausea, pain in extremity,
peripheral edema, pneumonia, pyrexia, upper respiratory
tract infection, and vomiting.
One or more SAEs were reported by 227 (39.4%) pa-
tients in the combined open-label long-term safety study
group, the 5 most common being pneumonia (3.6%),
sepsis (3.3%), congestive cardiac failure (2.8%), hyper-
kalemia (2.6%), and acute myocardial infarction (2.3%).
In total, 43 (7.5%) patients in the combined open-label275














Men 230 (54.0%) 219 (51.8%) 312 (54.2%)
Age, years 57 (12) 56 (13) 57 (12)
Race
White 208 (48.8%) 210 (49.6%) 286 (49.7%)
Black or African
American
185 (43.4%) 194 (45.9%) 252 (43.8%)
Native Hawaiian or other Pacific Islander 5 (1.2%) 2 (0.5%) 3 (0.5%)
Asian 15 (3.5%) 8 (1.9%) 18 (3.1%)
American Indian or Alaska
Native
2 (0.5%) 1 (0.2%) 2 (0.3%)
Other 10 (2.3%) 8 (1.9%) 15 (2.6%)
Missing 1 (0.2%) 0 (0%) 0 (0%)
Primary cause of CKD
Diabetes 192 (45.1%) 197 (46.6%) 260 (45.1%)
Hypertension 142 (33.3%) 146 (34.5%) 203 (35.2%)
Nephropathies 60 (14.1%) 49 (11.6%) 70 (12.2%)
Congenital renal disease 13 (3.1%) 11 (2.6%) 14 (2.4%)
Other 16 (3.8%) 17 (4.0%) 25 (4.3%)
Unknown 3 (0.7%) 3 (0.7%) 4 (0.7%)
Frequency of HD, ×/wk
2 3 (0.7%) 1 (0.2%) 1 (0.2%)
3 423 (99.3%) 422 (99.8%) 575 (99.8%)
Dosing frequency, ×/wk
1 167 (39.2%) 159 (37.6%) 236 (41.0%)
2 64 (15.0%) 62 (14.7%) 76 (13.2%)
3 195 (45.8%) 201 (47.5%) 263 (45.7%)
Missing 0 (0%) 1 (0.2%) 1 (0.2%)
Hb, g/dL 10.4 (0.7) 10.4 (0.8)b 10.4 (0.7)
Hematocrit, % 32.9 (2.7) 33.0 (2.7)b 32.9 (2.7)
Ferritin, ng/mL 934 (412) 941 (431) 946 (410)
TSAT, % 33.6 (12.0) 34.8 (12.2) 34.7 (12.4)
Medical history of comorbid
conditions present at baseline
Hypertension 419 (98.4%) 415 (98.1%) 568 (98.6%)
Diabetes 273 (64.1%) 267 (63.1%) 362 (62.8%)
Thromboembolism including myocardial
infarction and cerebrovascular accident
176 (41.3%) 150 (35.5%) 213 (37.0%)
Vascular access thrombosis 41 (9.6%) 37 (8.7%) 48 (8.3%)
Use of iron supplementation
At baseline 214 (50.2%) 212 (50.1%) 294 (51.0%)
During treatment 325 (76.3%) 333 (78.7%) 499 (86.6%)
Note: Values expressed as number (percent) or mean (standard deviation).
Abbreviations: CKD, chronic kidney disease; Hb, hemoglobin; HD, hemodialysis; TSAT, transferrin saturation.
aPercentages for Race may not sum to 100 because patients could select multiple races and because of rounding. Percentages for other characteristics also may not
sum to 100 because of rounding.
bMean (standard deviation) Hb and hematocrit based on data for 422 patients treated with epoetin alfa-epbx.
Original Researchlong-term safety study group experienced a treatment-
emergent SAE resulting in death. The most common
cause of death in the combined open-label long-term
safety study group was cardiovascular disease (n = 17).
Other causes of death were nervous system disorders
(n = 8), renal disorders, sepsis (n = 5 each), hemorrhage
(n = 3), acute respiratory failure (n = 2), pulmonary
embolism, hypoglycemia, and unknown cause (n = 1276each). Forty of the 43 treatment-emergent SAEs resulting
in death were considered by the investigators to be
probably not related or not related to study drug; 3
(intracerebral hemorrhage, myocardial infarction, and
cardiorespiratory arrest) were considered by the in-
vestigators to be possibly related to study drug.
In the combined open-label long-term safety study
group, 38 (6.6%) patients experienced an AE leadingKidney Med Vol 1 | Iss 5 | September/October 2019










No. of events 1,556 1,419
Patients with event
≥1 AE 318 (74.6%) 321 (75.9%)
≥1 treatment-
related AEa
18 (4.2%) 14 (3.3%)
≥1 severe AEb 67 (15.7%) 64 (15.1%)





15 (3.5%) 13 (3.1%)
Discontinuation
from study due to
an AE
10 (2.3%) 10 (2.4%)
AE resulting in
deathc




255 (59.9%) 268 (63.4%)
≥1 AE of special
interest
50 (11.7%) 64 (15.1%)
Treatment-
emergent AE
in ≥5% of patients
in either treatment
groupe
Diarrhea 33 (7.7%) 26 (6.1%)




30 (7.0%) 32 (7.6%)
Hypotension 29 (6.8%) 15 (3.5%)
Muscle spasm 28 (6.6%) 31 (7.3%)
Dyspnea 26 (6.1%) 25 (5.9%)
Cough 25 (5.9%) 21 (5.0%)
Dizziness 25 (5.9%) 23 (5.4%)
Pain in extremity 22 (5.2%) 17 (4.0%)
Vomiting 21 (4.9%) 32 (7.6%)
Headache 19 (4.5%) 29 (6.9%)
Hypertension 19 (4.5%) 24 (5.7%)
Fall 16 (3.8%) 22 (5.2%)
Note: Values expressed as number (percent).
Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory
Activities; SAE, serious adverse event.
aTreatment-related AEs include those considered as definitely, probably, or
possibly related to study drug, as well as those for which a causal relationship
was missing.
bSAEs also include those for whom severity was missing.
cExcludes patients who reported an AE resulting in death during the titration
period of EPOE-10-13.
dIncludes patients for whom treatment was required or other action was taken.
eAll investigator AE terms were coded using MedDRA version 14.1. Patients
are counted once within each system organ class for each preferred term and
may have had more than 1 AE.










No. of events 77 86
Patients with ≥1
eventa
50 (11.7%) 64 (15.1%)
Thromboembolic
events
26 (6.1%) 33 (7.8%)
Hypertension 21 (4.9%) 28 (6.6%)
Thrombosis of
vascular accessb
18 (4.2%) 28 (6.6%)
Cerebrovascular
events
6 (1.4%) 4 (0.9%)
Potential allergic
reactions
6 (1.4%) 10 (2.4%)
Myocardial
infarction
3 (0.7%) 4 (0.9%)
Seizures 1 (0.2%) 1 (0.2%)
Pure red blood
cell aplasia
0 (0%) 0 (0%)
Note: Values expressed as number (percent). All investigator AE terms were
coded using MedDRA version 14.1.
Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory
Activities.
aPatients were counted once within each category for each preferred term and
may have had more than 1 AE.
bThe AEs of special interest in the Thrombosis of vascular access category are
a subset of those in the Thromboembolic events category.
Original Researchto discontinuation of study drug treatment, the most
common being cardiac arrest, congestive heart failure
(0.7% each), cardiorespiratory arrest, cerebral hemorrhage
(0.5% each), acute myocardial infarction, myocardial
infarction, nausea, sepsis, and septic shock (0.3% each).Kidney Med Vol 1 | Iss 5 | September/October 2019Two of the 38 patients had AEs leading to discontinuation
of study drug treatment that were considered by the in-
vestigators to be possibly related to study drug. The most
common AEs of special interest in the combined open-
label long-term safety study group were thromboembolic
events (13.2%), thrombosis of vascular access (8.5%), and
hypertension (7.5%). Furthermore, there were no re-
ported cases of PRCA.
Clinical Laboratory, Vital Signs, and Other Safety
Assessments
Mean change from baseline to each assessment visit for
Hb level was minimal and similar between the combined
randomized groups (Table S3). Most patients had Hb
levels that remained within the target range, and the
incidence of patients who experienced an Hb excursion
(<8.0 or >12.0 g/dL) was generally similar between the
combined randomized groups. Additionally, there were
no clinically significant changes in other hematology
parameters or chemistry parameters during the ran-
domized studies. Furthermore, vital signs were similar
between combined randomized epoetin alfa-epbx and
epoetin alfa.
Mean change from baseline to each assessment visit for
Hb level was minimal for the combined open-label long-
term safety study group. Additionally, there were no
clinically significant changes in other hematology param-
eters or chemistry parameters during the open-label long-
term safety study.277
Original ResearchImmunogenicity
A total of 12 patients across the combined randomized
groups (epoetin alfa-epbx, n = 5; epoetin alfa, n = 7) were
confirmed anti-rhEPO antibody positive at 1 or more
visits during study conduct (ie, baseline, at any time
during treatment period, or end of treatment/follow-up/
withdrawal). Nine patients in the combined open-label
long-term safety study group were confirmed anti-rhEPO
antibody positive at 1 or more visits during study
conduct. Of these, only 2 did not test positive during the
randomized core studies. A summary of patients who
tested positive for anti-rhEPO antibodies at each visit is
provided in Table S4. No patient in any group developed
neutralizing antibodies. Overall, an evaluation of reported
events did not identify events of hypersensitivity consistent
with an immune response to epoetin.DISCUSSION
This analysis compares the safety of epoetin alfa-epbx and
epoetin alfa based on a pooled analysis of findings from 2
randomized double-blind clinical trials (EPOE-10-13 and
EPOE-10-01) conducted in HD patients with ane-
mia.13,14,17-19 This analysis also reports new data for the
long-term safety of epoetin alfa-epbx based on a pooled
analysis of findings from 2 open-label extension trials
(EPOE-11-04 and EPOE-11-03) for studies EPOE-10-13 and
EPOE-10-01. These analyses provide the largest and longest-
duration clinical safety summary to date for epoetin alfa-
epbx, with more than 800 patients treated with epoetin
alfa-epbx or epoetin alfa (mean exposure, w18 weeks)
across 2 randomized double-blind studies and 576 patients
treated with epoetin alfa-epbx (mean exposure, 40.0
weeks) across 2 open-label long-term safety studies.
Our pooled analysis of studies EPOE-10-13 and EPOE-
10-01 demonstrated similar safety between epoetin alfa-
epbx and epoetin alfa. Furthermore, pooled analysis of
open-label extension trials (EPOE-11-04 and EPOE-11-03)
for studies EPOE-10-13 and EPOE-10-01 demonstrated
that epoetin alfa-epbx was well tolerated, with no unex-
pected safety or immunogenicity signals with long-term
treatment. These findings add to the body of literature
demonstrating the safety of epoetin alfa biosimilars, such
as a study describing the safety and efficacy of the epoetin
alfa biosimilar, HX575.24
The AEs, including SAEs, observed in the safety popu-
lation for the combined randomized studies were generally
similar between epoetin alfa-epbx and epoetin alfa and
were concordant with the type and incidences of AEs
described for epoetin alfa.22,23 These findings reinforce
previous conclusions of similar safety of epoetin alfa-epbx
to epoetin alfa.13,14,19 The open-label extension trials
provide new safety data, allowing for evaluation of long-
term safety with prolonged exposure to epoetin alfa-
epbx. The incidence of AEs (86.5%) and SAEs (39.4%)
for the combined open-label long-term safety study group
is likely attributable to the longer duration of treatment278(mean exposure, 40.0 vs w18 weeks). Nonetheless, in the
long-term safety study, no new safety signals were iden-
tified. Types of AEs observed for the combined open-label
long-term safety study group were consistent with those
historically described for the reference product, epoetin
alfa. Additionally, there were no clinically significant
changes in hematology or chemistry parameters during the
randomized studies and the open-label long-term safety
study. Furthermore, Hb levels were stable throughout the
duration of the studies and remained within target range
for most patients.
ESKD is associated with higher mortality risk.25,26
Furthermore, the leading cause of death among patients
with ESKD is cardiovascular disease25,26; therefore, the car-
diovascular events observed during this analysis of the
epoetin alfa-epbx clinical development program are consis-
tent with expectations for an HD population. Infection,
bacteremia, and sepsis are also major sources of morbidity
and mortality in patients with ESKD receiving maintenance
HD therapy.27-29 Therefore, the 2 deaths due to sepsis and 1
death due to infectious peritonitis, which occurred in pa-
tients receiving epoetin alfa-epbx and were considered not
related or probably not related to the study drug, are also
consistent with expectations for an HD population.
PRCA is a rare hematologic disorder that may develop
after treatment with erythropoiesis-stimulating agents
(ESAs) due to the production of anti-erythropoietin
neutralizing antibodies.30 Previously described cases of
ESA-induced antibody-mediated PRCA predominantly
occurred in patients who received a particular formulation
of an epoetin alfa product (Eprex/Erypo; Janssen-Cilag
GmbH, Neuss, Germany) marketed outside of the United
States, and only when the drug was administered SC.31-33
However, in our studies, route of administration did not
detectably influence the risk for developing antibody-
mediated PRCA with erythropoietin products because
there were no reported events of PRCA in the epoetin alfa-
epbx clinical development program.
As a continuation of initial treatment in the randomized
studies, the open-label extension trials provided safety data
for epoetin alfa-epbx when administered either SC for up
to 64 weeks (16.0 months) or IV for up to 72 weeks (18.0
months). Accordingly, these studies are helpful in the
evaluation of AEs that may develop with long-term epoetin
treatment. The latency period for PRCA may be longer,
though, because previously described cases of ESA-induced
PRCA were diagnosed after a median treatment duration of
9.1 months for patients receiving Eprex/Erypo, 18.0
months for patients receiving epoetin beta, and 24.8
months for patients receiving Epogen.31 However, anti-
erythropoietin antibodies are likely to develop earlier and
may be present after 3 months of treatment.30 No patient
in the epoetin alfa-epbx clinical development program
developed neutralizing antibodies. Furthermore, reported
events within the category of potential allergic reactions
were generally identified as having an alternative etiology
or pertinent medical history that excluded true epoetin-Kidney Med Vol 1 | Iss 5 | September/October 2019
Original Researchrelated hypersensitivity reactions. Overall, these findings
suggest that there is no impact of immunogenicity on the
safety of epoetin alfa-epbx.
Based on intended design features of trials included in this
analysis, the long-term safety study did not include epoetin
alfa as a comparator, and cumulative exposure to study drug
in the overall programwas greater for epoetin alfa-epbx than
for epoetin alfa. These factors may limit the ability to draw
comparisons between treatment arms when the long-term
safety study data are included in the analysis. However, no
new safety signalswere identified in the open-label extension
trials; the types of AEs observed for the combined open-label
long-term safety study group were consistent with those
historically described for the reference product. This analysis
may also be limited by the short duration of follow-up in the
randomized studies and the potential for selection bias
among patients included in the open-label extension trials.
Nonetheless, one strength of this analysis is the inclusion of
data from 2 randomized controlled trials, which minimizes
the potential for confounding.
In conclusion, this analysis reinforces previous conclu-
sions of similar safety of epoetin alfa-epbx to the reference
product, epoetin alfa, based on a pooled analysis of the
experience in 2 randomized double-blind clinical
studies.13,14,19 Furthermore, pooled analysis of new data
from 2 supportive open-label extension trials demon-
strated that epoetin alfa-epbx was well tolerated and had
no unexpected safety or immunogenicity signals during
long-term treatment in HD patients with anemia.SUPPLEMENTARY MATERIAL
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